Literature DB >> 31994176

Cell line-based assessment of BTK inhibitors.

Günter Krause1,2, Floyd Hassenrück1,2, Michael Hallek1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31994176      PMCID： PMC7161538          DOI： 10.1111/bph.14948

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  6 in total

1.  An efficient rapid system for profiling the cellular activities of molecular libraries.

Authors:  Jonathan S Melnick; Jeff Janes; Sungjoon Kim; Jim Y Chang; Daniel G Sipes; Drew Gunderson; Laura Jarnes; Jason T Matzen; Michael E Garcia; Tami L Hood; Ronak Beigi; Gang Xia; Richard A Harig; Hayk Asatryan; S Frank Yan; Yingyao Zhou; Xiang-Ju Gu; Alham Saadat; Vicki Zhou; Frederick J King; Christopher M Shaw; Andrew I Su; Robert Downs; Nathanael S Gray; Peter G Schultz; Markus Warmuth; Jeremy S Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

2.  A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.

Authors:  Fu Gui; Jie Jiang; Zhixiang He; Li Li; Yunzhan Li; Zhou Deng; Yue Lu; Xinrui Wu; Guyue Chen; Jingyi Su; Siyang Song; Yue-Ming Zhang; Cai-Hong Yun; Xin Huang; Ellen Weisberg; Jianming Zhang; Xianming Deng
Journal:  Br J Pharmacol       Date:  2019-12-09       Impact factor: 8.739

3.  Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.

Authors:  Shenqiu Wang; Sayan Mondal; Chunying Zhao; Marjan Berishaj; Phani Ghanakota; Connie Lee Batlevi; Ahmet Dogan; Venkatraman E Seshan; Robert Abel; Michael R Green; Anas Younes; Hans-Guido Wendel
Journal:  JCI Insight       Date:  2019-06-20

4.  Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.

Authors:  Elisa Göckeritz; Verena Vondey; Anna Guastafierro; Maja Pizevska; Floyd Hassenrück; Lars Neumann; Michael Hallek; Günter Krause
Journal:  Br J Haematol       Date:  2017-06-01       Impact factor: 6.998

5.  PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

Authors:  Anella Yahiaoui; Sarah A Meadows; Rick A Sorensen; Zhi-Hua Cui; Kathleen S Keegan; Robert Brockett; Guang Chen; Christophe Quéva; Li Li; Stacey L Tannheimer
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

Review 6.  New roles for B cell receptor associated kinases: when the B cell is not the target.

Authors:  Phuong-Hien Nguyen; Emanuel Niesen; Michael Hallek
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.